[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-383863-105":59,"doc-detail-383863-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cancer-of-unknown-primary-cup-through-the-lens-of-precision-oncology-a-single-institution-perspective","Cancer of unknown primary (CUP) through the lens of precision oncology - a single institution perspective","","Precision oncology seeks to expand treatment options for patients with cancer of unknown primary (CUP), where standard choices are limited. This single-center observational study retrospectively analyzed unfavorable CUP cases discussed at a molecular tumor board within the Comprehensive Cancer Center Munich LMU. Clinically relevant variants were detected in 74% of 61 patients, with 64% receiving therapeutic recommendations. Implemented recommendations led to no clinical benefit in the small subset where applied, highlighting the need for earlier CGP integration. ",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cancer-of-unknown-primary-cup-through-the-lens-of-precision-oncology-a-single-institution-perspective/383863/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cancer-of-unknown-primary-cup-through-the-lens-of-precision-oncology-a-single-institution-perspective/383863.png","ImageObject",300,407,{"name":92,"@type":93},"Alex Sinclair","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the purpose of using precision oncology for CUP patients in this study?","Question",{"text":112,"@type":113},"To highlight how a molecular tumor board supports therapeutic management for advanced, hard-to-treat CUP patients by leveraging comprehensive genomic profiling and targeted therapies.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were CUP patients analyzed in the study?",{"text":117,"@type":113},"Unfavorable CUP patients presented to the molecular tumor board at a single tertiary center were analyzed retrospectively, using descriptive statistics for reported findings.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main results regarding variant detection and therapeutic recommendations?",{"text":121,"@type":113},"Clinically relevant variants were detected in 74% of patients, and 64% of those cases received therapeutic recommendations based on the molecular tumor board.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},383863,1790624424,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144},1099523882182,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Journal of Cancer Research and Clinical Oncology (2023) 149:8225–8234  \n[https://doi.org/10.1007/s00432-023-04741-y](https://doi.org/10.1007/s00432-023-04741-y)  \nCancer of unknown primary (CUP) through the lens of precision oncology: a single institution perspective  \nL. Weiss1,2,10 · K. Heinrich1 · D. Zhang1,3 · K. Dorman1,3 · K. Rühlmann2 · K. Hasselmann2 · F. Klauschen3,4 ·  \nJ. Kumbrink3,4 · A. Jung3,4 · M. Rudelius4 · A. Mock4 · Steffen Ormanns4 · W. G. Kunz5 · D. Roessler6,10 · G. Beyer6,10 ·  \nS. Corradini9 · L. Heinzerling7,8 · M. Haas1 · M. von Bergwelt‑Baildon1,3 · S. Boeck1,2,3 · V. Heinemann1,2 ·  \nC. B. Westphalen1,2,3,10  \nReceived: 10 February 2023 / Accepted: 2 April 2023 / Published online: 16 April 2023 © The Author(s) 2023  \nAbstract  \nPurpose For patients with cancer of unknown primary (CUP), treatment options are limited. Precision oncology, the interplay of comprehensive genomic profiling (CGP) and targeted therapies, aims to offer additional treatment options to patients with advanced and hard-to-treat cancers. We aimed to highlight the use of a molecular tumor board (MTB) in the therapeutic management of CUP patients.  \nMethods In this single-center observational study, CUP patients, presented to the MTB of the Comprehensive Cancer Center Munich LMU, a tertiary care center, were analyzed retrospectively. Descriptive statistics were applied to describe relevant findings.  \nResults Between June 2016 and February 2022, 61 patients with unfavorable CUP were presented to the MTB, detected clinically relevant variants in 74%(45/61) of patients, of which 64%(29/45) led to therapeutic recommendation. In four out of 29 patients (14%), the treatment recommendations were implemented, unfortunately without resulting in clinical benefit. Reasons for not following the therapeutic recommendation were mainly caused by the physicians’ choice of another therapy (9/25, 36%), especially in the context of worsening of general condition, lost to follow-up (7/25, 28%) and death (6/25, 24%) . Conclusion CGP and subsequent presentation to a molecular tumor board led to a high rate of therapeutic recommendations in patients with CUP. Recommendations were only implemented at a low rate; however, late GCP diagnostic and, respectively, MTB referral were found more frequent for the patients with implemented treatment. This contrast underscores the need for early implementation of CGP into the management of CUP patients.  \nKeywords Precision oncology · Personalized medicine · Molecular tumor board · Cancer of unknown primary · CUP syndrome · Comprehensive genomic profiling  \n* C. B. Westphalen[cwestpha@med.lmu.de](cwestpha@med.lmu.de)  \n1 Department of Medicine III, University Hospital, LMU Munich, Munich, Germany  \n2 Comprehensive Cancer Center Munich, University Hospital, LMU Munich, Munich, Germany  \n3 German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany  \n4 Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany  \n5 Department of Radiology, University Hospital, LMU Munich, Munich, Germany  \n6 Department of Medicine II, University Hospital, LMU Munich, Munich, Germany  \n7 Department of Dermatology, University Hospital, LMU Munich, Munich, Germany  \n8 Department of Dermatology, University Hospital Erlangen, Erlangen, Germany  \n9 Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany  \n10 Bavarian Cancer Research Center (BZKF), Munich, Germany  \nIntroduction  \nCancer of unknown primary (CUP) comprises a heterogeneous group of metastatic malignancies, in which extensive clinical and diagnostic work-up including physical examination, radiological imaging, and histopathological investigation, does not lead to the identification of a primary site (Fizazi et al. 2015) . While 3–5% of all malignancies are classified as CUPs, the underlying biology of these cancers remains mostly unknown (Pentheroudakiset al. 2007), and the prognosis for patients with CUP is generally poor with","cbCaiuOoOt0u0q1s","https://ap.wps.com/l/cbCaiuOoOt0u0q1s","pdf",623871,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusion\n# Introduction\n## CUP overview and prognosis\n## Role of comprehensive genomic profiling","[{\"question\":\"What is the purpose of using precision oncology for CUP patients in this study?\",\"answer\":\"To highlight how a molecular tumor board supports therapeutic management for advanced, hard-to-treat CUP patients by leveraging comprehensive genomic profiling and targeted therapies.\"},{\"question\":\"How were CUP patients analyzed in the study?\",\"answer\":\"Unfavorable CUP patients presented to the molecular tumor board at a single tertiary center were analyzed retrospectively, using descriptive statistics for reported findings.\"},{\"question\":\"What were the main results regarding variant detection and therapeutic recommendations?\",\"answer\":\"Clinically relevant variants were detected in 74% of patients, and 64% of those cases received therapeutic recommendations based on the molecular tumor board.\"}]","Cancer of unknown primary (CUP) through the lens of precision oncology - a single institution perspective | PDF",1790259957,25]